Randomized Phase 2 Study of Tivantinib (ARQ 197) Plus Erlotinib vs. Single-agent Chemotherapy in Previously Treated KRAS Mutant Advanced Non-Small Cell Lung Cancer (NSCLC)

Bruno Bastos

Randomized Phase 2 Study of Tivantinib (ARQ 197) Plus Erlotinib vs. Single-agent Chemotherapy in Previously Treated KRAS Mutant Advanced Non-Small Cell Lung Cancer (NSCLC)

Bruno Bastos

Research output: Contribution to conference › Presentation

Original language	American English
State	Published - Nov 2014
Event	2014 Chicago Multidisciplinary symposium in Thoracic Oncology - Duration: Nov 1 2014 → …

Conference

Conference	2014 Chicago Multidisciplinary symposium in Thoracic Oncology
Period	11/1/14 → …

Disciplines

Medicine and Health Sciences

Cite this

@conference{b57c4f259a474226ba63068d544fb793,

title = "Randomized Phase 2 Study of Tivantinib (ARQ 197) Plus Erlotinib vs. Single-agent Chemotherapy in Previously Treated KRAS Mutant Advanced Non-Small Cell Lung Cancer (NSCLC)",

author = "Bruno Bastos",

year = "2014",

month = nov,

language = "American English",

note = "2014 Chicago Multidisciplinary symposium in Thoracic Oncology ; Conference date: 01-11-2014",

}